

Anti-Tumor-Associated Glycoprotein (TAG-72) [B72.3]

Catalog No.	Description			
AM054-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system			
AM054-10M	-10M 10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive TM Detection Systems and i6000 TM Automated Staining Systems			
MU054-UC	4-UC1 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system			
MU054-5UC 0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system				
AX054-YCD Ready-to-Use Antibody in Barcode labele vial for use on the Xmatrx [®] Elite Staining System, 160 tests				
AX054-50D Ready-to-Use Antibody in Barcode labele vial for use on the Xmatrx [®] Elite Staining System, 50 tests				
AX054-4M	Ready-to-Use Antibody in Barcode labeled vial for use on the NanoVIP [®] Staining System, 50 tests			

Clone	Species	Ig Class
B72.3	Mouse	IgG1

Intended Use

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Tumor-associated glycoprotein (TAG-72) in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

Summary and Explanation

Tumor-Associated Glycoprotein 72 (TAG-72) is an oncofetal mucin antigen expressed by normal secretory endometrium and most human adenocarcinomas, including colorectal, gastric, pancreatic, mammary, and ovarian. Antibody B72.3 recognizes a carbohydrate epitope identified as sialylated Tn antigen. This antigen is expressed by invasive ductal breast carcinomas, colon, esophageal, lung and endometrial adenocarcinomas. It is not expressed by leukemias, lymphomas, sarcomas, mesotheliomas, melanomas, benign tumors, or non-endometrial normal tissues. TAG-72 expression in fetal tissue is only observed in tissues of the gastrointestinal tract, including the colon, esophagus and stomach.

Storage and Handling

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

Principles of the Procedure

Antigen detection by immunohistochemistry (<u>IHC</u>) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The <u>primary</u> <u>antibody</u> may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

Reagents Provided

Mouse Monoclonal Antibody to Tumor-associated glycoprotein (TAG-72) is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09% sodium azide.

Dilution of Primary Antibody

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

Recommended Protocol

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations		
Control Tissue	Breast Carcinoma as available with Biogenex FB-054M* & FG-054M*		
Recommended Dilution for Concentrated Antibody	1:50-100 in HK156		
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)		
Recommended Pretreatment (Xmatrx & NanoVIP)	EZ-AR2 Elegance (HX032-YCD & HX046-08XN)		
Antibody Incubation (Manual/i6000)	30-60 min at RT		
Antibody Incubation (Xmatrx & NanoVIP)	30-60 min at 25°C		
Detection System for Manual, Xmatrx, NanoVIP & i6000systems***	Use BioGenex Two-Step OR One-Step Super Sensitive [™] Polymer-HRP IHC Detection System/DAB; see p. 2 for more information		

*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx & NanoVIP requires micro chamber slides.

Pretreatment times will vary based on individual microwave power. *For automation systems (Xmatrx-Elite, NanoVIP & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	K
Document No.	932-054M-EN	Release Date	11-May-2022



CE _{Emergo}	Europe, Prinsessegracht	20, 2514AP	The Hague, The	Netherlands
EC REP				

Detection	Two-Step	One-Step	Link and	
System	HRP Kit	HRP Kit	Label Kit	
Manual	QD440-XAKEN (1000 Test) QD430-XAKEN (1000 Test)	QD630-XAKEN (1000 Test)	QP300- XAKE (1000 Test)	
	QD420-YIKEN (500 Test) QD400-60KE (60 Test)	QD620-XAKEN (500 Test)	QP900-9LE (500 Test)	
Xmatrx -	QD550-YCDEN	QD610-YADEN	N/A	
Automation	(200 Test)	(200 Test)		
NanoVIP-	QD551-YCDEN	QD611-YADEN	N/A	
Automation	(100 Test)	(100 Test)		
i6000 -	QD410-YAXEN	QD610-YAXEN	N/A	
Automation	(200 Test)	(200 Test)		
For more information, visit <u>www.biogenex.com</u> .				

Precautions

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

Quality Control

Refer to BioGenex detection system documents for guidance on general quality control procedures.

Troubleshooting

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or <u>support@biogenex.com</u> or your local distributor to report unusual staining.

Expected Results


This antibody stains cytoplasm in positive cells in formalinfixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medicallyestablished diagnostic product or procedure.

Limitations of the Procedure

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems . Improper counterstaining and mounting may compromise the interpretation of results.

Bibliography

- 1. Bertoglio, S, et al. Semin Surg Oncol 15: 249-53, 1998.
- 2. Colcher, D, et al. Proc Natl Acad Sci USA 78:3199, 1978.
- 3. Horan Hand, P, et al. Cancer Res 45:833, 1985.
- 4. Johnson, VG, et al. Cancer Res 46:850, 1986.
- 5. Schlom, J, et al. J Tumormarker Oncology 2:3, 1987.
- Center for Disease Control. Decontamination of Laboratory Sink Drains to Remove Azide Salts. Center for Disease Control Manual Guide--Safety Management, No. CDC-22, Atlanta, Georgia. April 30, 1976.
- 7. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
- 8. Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. Lab Med 1983; 14:767-770.
- Omata M, Liew CT, Ashcavai M, Peters Rl. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. May, 1980; 73(5):626-632.
- U.S. Congress. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
- National Institute for Occupational Safety and Health, (NIOSH), Rockville, MD. Explosive azide hazard, Publication No. 78-127, 1976.



© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	K
Document No.	932-054M-EN	Release Date	11-May-2022